如果非要是在美国两种疫苗中选择,还是选Pfizer/biotech

前天接受了辉瑞mRNA疫苗第一剂注射,感觉反应比每年的Flu shot 要大。24 小时后全身发热出汗,还有轻微头痛。没有用任何对症药,今天一切正常。我建议对Flu shot有较大反应的同胞要有心理准备。要备好Tylenol等药物。
 
真实世界是连阿斯利康都轮不到打,还想挑挑拣拣?知不知道排队打阿斯利康的有多少人吗?
真实的世界是阿斯利康有效性差、副作用大,加拿大启用阿斯利康的时候恰是其他多国停打、禁用的时候。如果加拿大政府出于无奈把有缺陷的阿斯利康作为一种选择提供给民众,那么民众根据自己的情况选择不打也是对自己生命负责的表现。这是无可厚非的,因为政府不对接种阿斯利康的后果负责。
 
据说有11%的人听说是阿斯利康,扭头就走。。。

应该告诉这些人,如果再想约疫苗,必须等4个个月以上。
这个不合适。个人的情况不同,有人介意阿斯利康,有人不介意,但问题的核心是阿斯利康有缺陷。那就不介意的人打吧,反正不介意,物尽其用嘛。惩罚介意的人就不对了,因为阿斯利康作为有缺陷的疫苗已被多国叫停,此时政府胁迫民众打这种疫苗是不明智的。
 
血管堵塞不是因为疫苗种类吧。我觉得对个体来说,重要性按以下顺序:
1.重症防护
2.副作用
3.次数(只打一次可以尽快免疫,如果两次,中间间隔是危险期)
防疫有效率对个体来说是last thing need to worry about. 如果能够防止住院或者重症,小感冒过几天就好了,说不定还加强了免疫。当然对于群体来说,有效率越高越好
血管堵塞如果发生在脑部,就是我们通常说的中风吧?
 
打疫苗要抓紧,最好有什么打什么,因为疫苗需要时间建立抗体。。。年龄越大,约需要时间建立免疫力。

美国密歇根出现2百多人打了两针后的3周内还感染了covid,还死了三个。


 
打疫苗要抓紧,最好有什么打什么,因为疫苗需要时间建立抗体。。。年龄越大,约需要时间建立免疫力。

美国密歇根出现2百多人打了两针后的3周内还感染了covid,还死了三个。


可能是变异导致的,要不然两针后死三个太可怕了,要是中国疫苗,不是被笑上天了,问问方肘子怎么说
 
打疫苗要抓紧,最好有什么打什么,因为疫苗需要时间建立抗体。。。年龄越大,约需要时间建立免疫力。

美国密歇根出现2百多人打了两针后的3周内还感染了covid,还死了三个。


完全免疫后被感染的246人,没有看到所占比例是多少?死了3位,可是很严重的。

为什么不能写得清楚些呢?
 
完全免疫后被感染的246人,没有看到所占比例是多少?死了3位,可是很严重的。

为什么不能写得清楚些呢?

占啥比例?全部接种人数?

关键是这些人都是接种第二针后3个星期内感染的,3位死者中两位是65岁以上。

现在怀疑到底第二针以后要多久才能产生足够的抗体,当然这和人的免疫能力和年龄已经是否有existing condition都有关系。

也就是说,如果是个老人或者病秧子,打了疫苗也要万分小心。
 
占啥比例?全部接种人数?

关键是这些人都是接种第二针后3个星期内感染的,3位死者中两位是65岁以上。

现在怀疑到底第二针以后要多久才能产生足够的抗体,当然这和人的免疫能力和年龄已经是否有existing condition都有关系。

也就是说,如果是个老人或者病秧子,打了疫苗也要万分小心。
我的问题是,这246人占总数完全免疫人数是多少?比如以下的报道:

以色列2月报道60万人两针以后,608人感染,占0.1%。21人住院,其中7人重症,都有基础病,3人中度,11人轻症。

4:08 p.m. ET, February 17, 2021

Pfizer vaccine is about 95% effective against Covid-19, Israeli data shows

From CNN's Amir Tal and Elizabeth Cohen

A health worker fills a syringe with the Pfizer-BioNTech Covid-19 vaccine. Christof Stache/AFP/Getty Images

Data from more than 600,000 vaccinated Israelis shows the Pfizer vaccine is 95% effective, with only 21 vaccinated people ending up in the hospital with Covid-19, according to a press release from Maccabi Healthcare Services, Israel’s second largest healthcare provider.

The findings, while preliminary, suggest the vaccine remains remarkably effective in the real world and not just in the clinical trials conducted last year by Pfizer and BioNTech.

Maccabi looked at data from about 602,000 of its members who were at least one week past their second dose of the vaccine. Among them, 7 were hospitalized with severe symptoms, 3 with moderate symptoms, and 11 with mild symptoms.

All of the hospitalized members were over age 50, and half of them had a chronic health condition, such as morbid obesity, according to Ido Hadari, a Maccabi spokesman.

Among the 602,000 vaccinated members, tests showed that 608 became infected with Covid-19. Maccabi did not routinely test members, but of the 608, 35% chose to get tested because they had symptoms of Covid-19 and 65% chose to get tested because they had been exposed to someone with the virus.

Maccabi compared that infection rate with a group of 528,000 members who had not yet received the vaccine. In this control group, 20,621 people, or nearly 4%, were identified as having Covid-19.

Maccabi’s findings are similar to data released earlier this week by Israel’s largest healthcare provider, which found the vaccine was 94% effective. Pfizer’s clinical trial showed about the same efficacy.

 
后退
顶部